Ecolab Inc. ECL
We take great care to ensure that the data presented and summarized in this overview for ECOLAB INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ECL
View all-
Vanguard Group Inc Valley Forge, PA24MShares$5.81 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY21.7MShares$5.26 Billion0.12% of portfolio
-
State Street Corp Boston, MA11.3MShares$2.73 Billion0.12% of portfolio
-
Morgan Stanley New York, NY5.8MShares$1.4 Billion0.11% of portfolio
-
Bill Gates Bill & Melinda Gates Foundation Trust | Kirkland, Wa5.22MShares$1.26 Billion2.95% of portfolio
-
Geode Capital Management, LLC Boston, MA5.18MShares$1.25 Billion0.11% of portfolio
-
Wellington Management Group LLP Boston, MA5.15MShares$1.25 Billion0.24% of portfolio
-
Aristotle Capital Management, LLC Los Angeles, CA4.56MShares$1.1 Billion2.25% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.25MShares$1.03 Billion0.95% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.84MShares$929 Million0.26% of portfolio
Latest Institutional Activity in ECL
Top Purchases
Top Sells
About ECL
Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through Global Industrial, Global Institutional & Specialty, and Global Healthcare & Life Sciences segments. The Global Industrial segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, metals and mining, power generation, pulp and paper, commercial laundry, petroleum, refining, and petrochemical industries. The Global Institutional & Specialty segment provides specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government and education, and retail industries. Its Global Healthcare & Life Sciences segment offers specialized cleaning and sanitizing products to the healthcare, personal care, and pharmaceutical industries, such as infection prevention and surgical solutions, and end-to-end cleaning and contamination control solutions under the Ecolab, Microtek, and Anios brand names. The company's Other segment offers pest elimination services to detect, eliminate, and prevent pests, such as rodents and insects in restaurants, food and beverage processors, educational and healthcare facilities, hotels, quick service restaurant and grocery operations, and other institutional and commercial customers. This segment also provides colloidal silica for binding and polishing applications in semiconductor, catalyst, and aerospace component manufacturing, as well as chemical industries; and products and services that manage wash process through custom designed programs, premium products, dispensing equipment, water and energy management, and reduction, as well as real time data management. It sells its products through field sales and corporate account personnel, distributors, and dealers. The company was founded in 1923 and is headquartered in Saint Paul, Minnesota.
Insider Transactions at ECL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 19
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
79,585
-0.09%
|
$19,418,740
$244.23 P/Share
|
Nov 18
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
83,873
-0.14%
|
$20,632,758
$246.14 P/Share
|
Nov 18
2024
|
Alexander A. De Boo EVP & PRES - GLOBAL MARKETS |
SELL
Open market or private sale
|
Direct |
1,390
-26.56%
|
$340,550
$245.73 P/Share
|
Nov 18
2024
|
Alexander A. De Boo EVP & PRES - GLOBAL MARKETS |
BUY
Exercise of conversion of derivative security
|
Direct |
2,039
+28.04%
|
$218,173
$107.69 P/Share
|
Nov 15
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-0.17%
|
$24,500,000
$245.39 P/Share
|
Nov 14
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-0.11%
|
$24,800,000
$248.9 P/Share
|
Nov 13
2024
|
Arthur J Higgins |
SELL
Open market or private sale
|
Direct |
2,000
-7.09%
|
$498,000
$249.81 P/Share
|
Nov 13
2024
|
Arthur J Higgins |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+6.62%
|
$250,000
$125.67 P/Share
|
Nov 13
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
177,892
-0.2%
|
$44,295,108
$249.42 P/Share
|
Nov 12
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
126,436
-0.14%
|
$31,482,564
$249.07 P/Share
|
Nov 11
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,742
-0.08%
|
$12,435,500
$250.8 P/Share
|
Nov 08
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
89,828
-0.06%
|
$22,277,344
$248.5 P/Share
|
Nov 07
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
50,815
-0.06%
|
$12,449,675
$245.89 P/Share
|
Nov 07
2024
|
Christophe Beck CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
20,766
-13.1%
|
$5,108,436
$246.28 P/Share
|
Nov 07
2024
|
Christophe Beck CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,471
+22.5%
|
$2,618,397
$107.69 P/Share
|
Nov 06
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,287
-0.06%
|
$18,520,602
$246.25 P/Share
|
Nov 04
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
65,015
-0.05%
|
$15,863,660
$244.48 P/Share
|
Nov 01
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
322,662
-0.35%
|
$79,052,190
$245.79 P/Share
|
Oct 31
2024
|
William H Gates Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
409,136
-0.22%
|
$101,056,592
$247.59 P/Share
|
Sep 30
2024
|
John J Zillmer |
BUY
Grant, award, or other acquisition
|
Direct |
132
+0.29%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 40.6K shares |
---|---|
Exercise of conversion of derivative security | 100K shares |
Open market or private purchase | 2.1K shares |
Open market or private sale | 1.8M shares |
---|---|
Payment of exercise price or tax liability | 26K shares |